Company Filing History:
Years Active: 2009
Title: Innovator Spotlight: Peter Collins - Pioneer in Specific Binding Proteins
Introduction:
Peter Collins is a distinguished inventor based in Cambridge, GB, known for his groundbreaking work in the field of specific binding proteins. With a sharp focus on developing antibodies that target aberrant post-translationally modified forms of EGFR, Collins has made significant contributions to the field of molecular biology.
Latest Patents:
One of Collins' notable patents is titled "Specific binding proteins and uses thereof." This patent revolves around the creation of specific binding members, particularly antibodies and active fragments, that recognize abnormal glycosylated forms of EGFR. These binding members are designed to target the de2-7 EGFR variant at an epitope distinct from the junctional peptide, showcasing Collins' innovative approach to antibody development.
Career Highlights:
Peter Collins is currently affiliated with Abbott Laboratories Corporation, a renowned player in the pharmaceutical and healthcare industry. At Abbott Laboratories, Collins continues to drive innovation in the development of novel therapeutic antibodies and other biologics, leveraging his expertise in molecular biology and protein engineering.
Collaborations:
Collins has collaborated with esteemed professionals in the field, including Lloyd J Old and Terrance Grant Johns. Through these collaborations, Collins has been able to exchange ideas, share insights, and push the boundaries of antibody technology further. His partnerships with industry experts have undoubtedly enriched his work and led to groundbreaking innovations.
Conclusion:
In conclusion, Peter Collins stands out as a pioneer in the field of specific binding proteins, with a keen focus on developing antibodies targeting abnormal EGFR variants. His work at Abbott Laboratories Corporation and collaborations with industry peers highlight his commitment to advancing molecular biology and biologics. Collins' innovative spirit and dedication to scientific discovery continue to inspire the next generation of inventors in the biotechnology sector.